Scientific deep-dive

GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days

Semaglutide cut the risk of kidney failure, a large drop in kidney function, or death from a kidney or cardiovascular cause by 24% over a median 3.4 years. The label also warns of acute kidney injury in people dehydrated by vomiting or diarrhea. Both are true.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·3 citations

The answer to “is this bad for my kidneys” depends on the timescale. Over years, among people with chronic kidney disease to begin with, semaglutide lowered the combined risk of kidney failure, a large drop in kidney function, or a kidney or cardiovascular death by 24%.[1] Pooled across 13 trials, those heart and kidney benefits in chronic kidney disease are rated high certainty. Over days, the label warns about acute kidney injury in people who become dehydrated from vomiting or diarrhea, and some reported cases required dialysis.[3] Both are real, and the second is the one you can do something about this week.

The long-run picture

FLOW enrolled 3,533 people who had both type 2 diabetes and established kidney disease and randomized them to semaglutide or placebo, with a median follow-up of 3.4 years.[1] Its primary outcome bundled the events that matter most in kidney disease: kidney failure, a sustained fall of half or more in filtration rate, and death from kidney or cardiovascular causes. The standard filtration estimate is calculated from creatinine, which comes from muscle, so weight loss could in principle flatter it; a trial that measured filtration directly found that worry does not hold at around 10% weight loss.

FLOW. Everyone enrolled had both diabetes and established kidney disease; median follow-up 3.4 years.
OutcomeResult
Primary composite kidney outcome24% lower — HR 0.76 (95% CI 0.66–0.88)
Death from cardiovascular causesHR 0.71 (0.56–0.89)
Annual decline in filtration rateSlower by 1.16 mL/min/1.73m² per year

That last row is the one nephrologists look at. Kidney function declines with time in this population; a treatment that flattens the slope buys years before dialysis becomes the conversation. Our FLOW trial page sets the study out in full.

FLOW was stopped early, at a prespecified interim analysis, because the benefit had already crossed its boundary. That is the right call for participants and it systematically inflates the apparent size of an effect. The direction here is supported by a large trial over years; the precise 24% is the number to hold loosely.

The short-run warning

Now the other half, which appears in Section 5.5 of the label rather than in any trial headline. Since the drug reached the market, cases of sudden kidney injury have been reported in people taking semaglutide, some severe enough that dialysis was needed. The label is specific about the pattern: the majority occurred in patients whose nausea, vomiting or diarrhea led to dehydration.[3]

The usual mechanism is fluid loss, not the drug acting on the kidney.

That distinction matters because it changes what to do. A drug that damaged kidneys directly would be a reason to avoid it in kidney disease. A drug that occasionally causes enough vomiting to dehydrate someone is a reason to take dehydration seriously. That is manageable, and the same label asks prescribers to monitor it. Deliberate fluid loss, such as sweating off weight in a sauna, belongs on the same list; see sauna and sweating for weight loss. It matters more if you also take Jardiance, Farxiga or another SGLT2 inhibitor, since that class also pulls water out through the urine; see an SGLT2 and a GLP-1 together. The GLP‑1 itself is not a water pill: over weeks it tends to lower drinking and urine output, as set out in GLP-1 drugs, urination and thirst, and low urine volume is a well-established risk factor for kidney stones.

When vomiting or diarrhea stops being a nuisance. If you cannot keep fluids down for a day, or you are passing much less urine than usual, or you feel dizzy standing up, that is the pattern that precedes kidney injury. Call your prescriber instead of waiting it out. It matters more, not less, if you are also on an ACE inhibitor, an ARB or a diuretic, because those change how your kidneys handle low fluid. It matters for metformin too, for a different reason: impaired kidneys are the first risk factor its label names for lactic acidosis, which is worked through in metformin and a GLP-1 together.

What the systematic review adds

A 2025 Cochrane review assessed the benefits and harms of GLP-1 drugs across people with chronic kidney disease and diabetes at every stage from 1 to 5, with death, major cardiovascular events, kidney failure and severe hypoglycemia among its primary outcomes.[2] Cochrane reviews are the most conservative form of synthesis there is. They weight risk of bias heavily and are reluctant to overstate.

Its findings are more cautious than FLOW’s headline. Against placebo, GLP-1 drugs probably reduced death from any cause and major cardiovascular events, but probably had little or no effect on kidney failure or on composite kidney outcomes across the class, both at moderate certainty.[2] That gap matters, because FLOW was one trial of one drug, stopped early and funded by Novo Nordisk.

Reconciling the two halves

  • Chronic kidney disease on its own does not rule these drugs out. In the population that has it, the trial evidence points the other way. After a transplant there are no trials yet, only observational studies whose figures look almost too good.
  • The acute risk is downstream of the gastrointestinal effects, which are worst during dose escalation. That is when to be most careful about fluids, and our water intake calculator and side-effect timeline cover the window.
  • Kidney function is measurable, which puts this among the few risks on this site where you can simply ask for the number. If you have kidney disease or take drugs that affect the kidneys, ask what is being monitored and how often.
  • Dose-stacking and compounded vials complicate this, because the gastrointestinal effects scale with dose and an unverified concentration makes the dose uncertain (see what is in a compounded vial).

Frequently Asked Questions

Over years the evidence points the opposite way. Among 3,533 people who had diabetes and established kidney disease together, semaglutide cut the combined risk of kidney failure, a large fall in filtration, or a kidney or cardiovascular death by 24%. Over days, the label warns about acute kidney injury in people who become dehydrated from vomiting or diarrhea. That is a different mechanism on a different timescale.
Chronic kidney disease is not in itself a reason to avoid them, and the trial evidence in exactly that population showed benefit. It is a reason for your kidney function to be monitored, which is straightforward because it is a blood test.
Kidneys need adequate blood flow to filter. Sustained vomiting or diarrhea reduces circulating fluid volume, and the label records postmarketing cases of acute kidney injury, some requiring dialysis, occurring mostly in people who had those gastrointestinal reactions. The mechanism is the fluid loss rather than the drug acting on the kidney.
If you cannot keep fluids down for a day, are passing much less urine than usual, or feel dizzy on standing. That combination precedes kidney injury. An ACE inhibitor, an ARB or a diuretic raises the stakes further.
It was large, randomized and ran a median of 3.4 years, which is strong. Two caveats belong with it: it was stopped early at a prespecified interim analysis, which inflates apparent effect size, and it was funded by the manufacturer. A 2025 Cochrane review of the class in chronic kidney disease found probable benefits on death and major cardiovascular events, but little or no effect on kidney failure or composite kidney outcomes.

References

  1. 1.Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes New England Journal of Medicine. 2024. PMID: 38785209.
  2. 2.Natale P, Green SC, Tunnicliffe DJ, et al. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes Cochrane Database of Systematic Reviews. 2025. PMID: 39963952.
  3. 3.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 5.5 Acute Kidney Injury Due to Volume Depletion (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went

Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.

10 min read

GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026

In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.

7 min read

GLP-1 Drugs and Low Blood Sugar: Who Is Actually at Risk

A GLP-1 alone is a poor cause of hypoglycemia, because it prompts insulin only when glucose is already high. The risk belongs to what it is taken alongside, and the label says one combination has never been evaluated.

6 min read

Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off

Stopping Ozempic or Wegovy causes no withdrawal syndrome on either label. Appetite returns as semaglutide clears over about five weeks, and a 2026 BMJ meta-analysis found regain of about 0.8 kg a month. What helps keep weight off, and what women should know.

10 min read

Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ

Semaglutide produced injection site reactions in 1.4% against 1% on placebo. Tirzepatide runs 6–8% against 2%. If you react on one and not the other, that is not your technique.

5 min read

Ozempic and Gastroparesis: How Real Is “Stomach Paralysis”?

GLP-1 users are diagnosed with gastroparesis more often, about 6.5 per 1,000 a year on semaglutide against 2.1 on another weight drug. What the Ozempic and Mounjaro labels added and when, whether it reverses, and where MDL 3094 stands.

11 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.1

Collective

From $59/mo + membership

Get started →
Read full review →
6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →